Event-Free Survival and Safety With Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia: 5-Year Follow-Up of OPTIC (SOHO 2026) - Sep 1, 2026 - Abstract #CML-516; Location: LEVEL 3, HALL B3; P2 | "At 5 years, response-based ponatinib dosing of a 45-mg starting dose reduced to 15 mg was associated with longer EFS compared with lower starting doses. Overall, the safety profile was comparable across cohorts. These findings further support the clinical rationale for optimized response-based dosing with a 45-mg starting dose in patients with chronic-phase CML."
Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • BCR
|
|
Michael Deininger 1; Hagop Kantarjian 2; Jane Apperley 3; Bo Chao 4; Alexander Vorog 4; L Evan Reddick 4; Meliessa Hennessy 4; Jorge Cortes 5
|